<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002343</url>
  </required_header>
  <id_info>
    <org_study_id>048E</org_study_id>
    <secondary_id>CS 087287-000</secondary_id>
    <nct_id>NCT00002343</nct_id>
  </id_info>
  <brief_title>A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS</brief_title>
  <official_title>An Open-Label Randomized Pharmacokinetic/Pharmacodynamic Study of Mycobutin (Rifabutin) or Rifabutin in Combination With Myambutol (Ethambutol) for Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts &lt;= 100 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To optimize Mycobacterium avium Complex (MAC) prophylaxis in AIDS patients by measuring serum&#xD;
      rifabutin levels and adjusting the dose accordingly. To combine rifabutin with ethambutol to&#xD;
      examine the effect of combination therapy in preventing or delaying the incidence of MAC&#xD;
      bacteremia in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive oral rifabutin alone or rifabutin/ethambutol daily for 12&#xD;
      months, with possible continuation of medicine lifelong. Doses will be adjusted to maintain&#xD;
      minimum blood levels of the drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>Mycobacterium Avium-Intracellulare Infection</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  AZT, d4T, ddI, or ddC.&#xD;
&#xD;
          -  Antipneumocystis prophylaxis.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Short course (&lt; 14 days) of ciprofloxacin for acute infections.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS.&#xD;
&#xD;
          -  CD4 count &lt;= 100 cells/mm3.&#xD;
&#xD;
          -  NO prior or current MAC infection.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Antipneumocystis prophylaxis for at least 4 weeks prior to study entry.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior rifabutin.&#xD;
&#xD;
          -  Prior ethambutol.&#xD;
&#xD;
          -  Prior clarithromycin.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Positive tuberculin skin test (PPD &gt; 5 mm).&#xD;
&#xD;
          -  Active M. tuberculosis.&#xD;
&#xD;
          -  Perceived as unreliable or unavailable for frequent monitoring.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other antiretrovirals not specifically allowed.&#xD;
&#xD;
          -  All investigational drugs.&#xD;
&#xD;
          -  Other antimycobacterial therapy, such as clarithromycin, azithromycin, rifampin,&#xD;
             clofazimine, amikacin, streptomycin, isoniazid, cycloserine, ethionamide, and&#xD;
             ciprofloxacin (&gt;= 14 days).&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        Known hypersensitivity to rifabutin, rifampin, or other rifamycins and/or ethambutol.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Clofazimine.&#xD;
&#xD;
          -  Cycloserine.&#xD;
&#xD;
          -  Ethionamide.&#xD;
&#xD;
          -  Amikacin.&#xD;
&#xD;
          -  Ciprofloxacin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of California - Davis Med Ctr / CARES</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 1997</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Rifabutin</keyword>
  <keyword>Mycobacterium avium-intracellulare Infection</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Ethambutol</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

